Admission Date:  [**2128-2-17**]              Discharge Date:   [**2128-3-2**]  Date of Birth:  [**2046-3-23**]             Sex:   F  Service: CARDIOTHORACIC  Allergies: No Known Allergies / Adverse Drug Reactions  Attending:[**First Name3 (LF) 922**] Chief Complaint: chest pressure  Major Surgical or Invasive Procedure: [**2128-2-19**] cardiac catheterization [**2128-2-23**] Aortic valve replacement with a 21-mm [**Doctor Last Name **] Magna Ease aortic valve bioprosthesis, serial number [**Serial Number 31772**], model number 3300TFX.
She presented to the ED [**2128-2-13**] with epistaxsis; her INR was 6.7 and she was disharged home with coumadin on hold and returned for cardiac catherization for preoperative evaluation.
None [] Neuro: Grossly intact Pulses: Femoral      Right: 2+  Left: 2+ DP           Right: 1+  Left: 1+ PT           [**Name (NI) 167**]: 1+  Left: 1+ Radial       Right: 2+  Left: 2+  Carotid Bruit:  Right: soft bruit  Left: soft bruit   Pertinent Results: [**2128-3-2**] 04:36AM BLOOD WBC-10.2 RBC-3.29* Hgb-9.9* Hct-30.1* MCV-92 MCH-30.2 MCHC-33.0 RDW-16.0* Plt Ct-215 [**2128-2-17**] 09:19PM BLOOD WBC-14.5* RBC-3.59* Hgb-10.8* Hct-31.6* MCV-88 MCH-30.0 MCHC-34.1 RDW-12.8 Plt Ct-564* [**2128-2-17**] 09:19PM BLOOD Neuts-78.4* Lymphs-13.7* Monos-7.1 Eos-0.5 Baso-0.4 [**2128-3-2**] 04:36AM BLOOD Plt Ct-215 [**2128-3-2**] 04:36AM BLOOD PT-20.0* PTT-29.7 INR(PT)-1.8* [**2128-2-17**] 09:19PM BLOOD PT-20.2* PTT-39.3* INR(PT)-1.9* [**2128-2-16**] 09:50AM BLOOD PT-27.3* INR(PT)-2.7* [**2128-2-23**] 04:52PM BLOOD Fibrino-215 [**2128-3-2**] 04:36AM BLOOD Glucose-114* UreaN-35* Creat-1.3* Na-138 K-3.5 Cl-96 HCO3-37* AnGap-9 [**2128-3-1**] 06:13AM BLOOD Glucose-91 UreaN-38* Creat-1.4* Na-139 K-3.5 Cl-95* HCO3-36* AnGap-12 [**2128-2-27**] 02:02AM BLOOD Glucose-78 UreaN-31* Creat-1.9* Na-136 K-3.5 Cl-96 HCO3-28 AnGap-16 [**2128-2-16**] 09:50AM BLOOD UreaN-25* Creat-1.3* Na-135 K-4.8 Cl-97 HCO3-25 AnGap-18 [**2128-3-1**] 06:13AM BLOOD ALT-10 AST-31 LD(LDH)-316* AlkPhos-69 Amylase-33 TotBili-1.1 [**2128-2-19**] 07:35AM BLOOD ALT-32 AST-25 LD(LDH)-264* AlkPhos-93 Amylase-31 TotBili-0.6 [**2128-2-28**] 06:00AM BLOOD ALT-13 AST-40 AlkPhos-87 Amylase-33 TotBili-1.7* [**2128-3-2**] 04:36AM BLOOD Calcium-8.1* Phos-2.6* Mg-1.8 [**2128-2-17**] 09:19PM BLOOD Calcium-8.9 Phos-3.2 Mg-2.0  ABDOMINAL ULTRASOUND:  Liver parenchyma is homogeneous with no focal hepatic lesions.
Mild persistent wall thickening in the region of the fundus measuring slightly greater than 4 mm is little changed from [**2124**] exam and may represent underlying adenomyomatosis.
No secondary findings of acute cholecystitis on today's examination or biliary ductal dilatation.
COMPARISON: Portable chest radiograph from [**2128-2-27**].
Echocardiographic Measurements Results  Measurements  Normal Range Left Ventricle - Septal Wall Thickness:  *1.3 cm  0.6 - 1.1 cm Left Ventricle - Inferolateral Thickness:  *1.3 cm  0.6 - 1.1 cm  Left Ventricle - Diastolic Dimension:  4.4 cm  <= 5.6 cm Left Ventricle - Ejection Fraction:  50% to 55%  >= 55% Aorta - Annulus:  2.2 cm  <= 3.0 cm Aorta - Sinus Level:  3.1 cm  <= 3.6 cm Aorta - Sinotubular Ridge:  2.2 cm  <= 3.0 cm Aorta - Ascending:  3.1 cm  <= 3.4 cm Aorta - Arch:  2.6 cm  <= 3.0 cm Aorta - Descending Thoracic:  *2.7 cm  <= 2.5 cm Aortic Valve - Peak Velocity:  *4.2 m/sec  <= 2.0 m/sec Aortic Valve - Peak Gradient:  *72 mm Hg  < 20 mm Hg Aortic Valve - Mean Gradient:  40 mm Hg Aortic Valve - LVOT VTI:  18 Aortic Valve - Valve Area:  *0.5 cm2  >= 3.0 cm2  Findings LEFT ATRIUM: No spontaneous echo contrast in the body of the [**Name Prefix (Prefixes) **] [**Last Name (Prefixes) **] LAA.
Mild (1+) MR. TRICUSPID VALVE: Normal tricuspid valve leaflets.
GENERAL COMMENTS: A TEE was performed in the location listed above.
Overall left ventricular systolic function is normal (LVEF>55%).
The LV systolic function remains normal; the chamber size is small, consistent with relative hypovolemia.
Brief Hospital Course: Presented with chest pain, and underwent evaluation which including ruling out for myocardial infarction.
She completed preoperatve workup and underwent aortic valve replacement and coronary artery bypass graft surgery on [**2128-2-23**].
She was improving however and was extubated [**2-26**], but creatinine increased to 1.9 peak [**2-27**] - acute kidney injury, and has trended down with creatinine 1.3 on discharge, which ace inhibitor was not initiated and should be considered as an outpatient.
Surgery was consulted for evaluation due to known hernia and there was no acute processes and lever functions were normal.
Medications on Admission: AMIODARONE - 200 mg Tablet - 2 Tablet(s) by mouth DAILY (Daily)  BUPROPION HCL [BUDEPRION SR] - 150 mg Tablet Extended Release - 1 Tablet(s) by mouth once a day for 3 days and then twice a day there after HYDROXYCHLOROQUINE [PLAQUENIL] - 200 mg Tablet - 1 (One) Tablet(s) by mouth twice a day PRAVASTATIN [PRAVACHOL] - 20 mg Tablet - 1 Tablet(s) by mouth once a day WARFARIN - 2.5 mg Tablet - 1 Tablet(s) by mouth Once Daily at 4  PM ASPIRIN - (OTC) - 81 mg Tablet, Chewable - 1 Tablet(s) by mouth  once a day CALCARB 600 - 600 mg (1,500 mg) Tablet - 1 (One) Tablet(s) by mouth twice a day ERGOCALCIFEROL (VITAMIN D2) [VITAMIN D] - 1,000 unit Tablet - 1  Tablet(s) by mouth daily MULTIVITAMIN-MINERALS-LUTEIN [CENTRUM SILVER] - (OTC) - Tablet - 1 (One) Tablet(s) by mouth daily OMEGA-3 FATTY ACIDS [FISH OIL] - (OTC) - 1,000 mg Capsule - once a day   Discharge Medications: 1. bupropion HCl 150 mg Tablet Extended Release Sig: One (1) Tablet Extended Release PO BID (2 times a day).
Outpatient Lab Work Labs: PT/INR Coumadin for Atrial Fibrillation Goal INR 2.0-2.5 First draw [**3-3**] Then please do INR checks Monday, Wednesday, and Friday for 2 weeks then decrease to twice a week if on stable dosing Rehab physician to monitor and dose coumadin while at rehab - please arrange coumadin follow up with PCP prior to discharge from rehab 6. warfarin 1 mg Tablet Sig: goal INR 2-2.5 Tablets PO once a day: to be dosed by rehab physician based on INR results - received 1mg on [**3-31**], [**3-1**], [**3-2**] - INR [**3-2**] 1.8.
Answering service will contact on call person during off hours**  Labs: PT/INR Coumadin for Atrial Fibrillation Goal INR 2.0-2.5 First draw [**3-3**] Then please do INR checks Monday, Wednesday, and Friday for 2 weeks then decrease to twice a week if on stable dosing Rehab physician to monitor and dose coumadin while at rehab - please arrange coumadin follow up with PCP prior to discharge from rehab    Completed by:[**2128-3-2**
